trending Market Intelligence /marketintelligence/en/news-insights/trending/CG7y74sM5BIunN2XMEy5qQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eiger drug reduces viral load in Hepatitis Delta patients, midstage study shows

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eiger drug reduces viral load in Hepatitis Delta patients, midstage study shows

Eiger BioPharmaceuticals Inc.'s experimental drug, pegylated interferon lambda, reduced viral load in a mid-stage study on patients infected with the Hepatitis Delta virus.

The infection, caused by the Hepatitis Delta virus, or HDV, occurs only in patients already harboring Hepatitis B virus and leads to more severe liver disease.

The study, called LIMT HDV, tested two doses of the pegylated interferon lambda injection among 33 patients from New Zealand, Israel and Pakistan. Interferons are proteins manufactured and released by body's cells when they get infected with viruses, bacteria, parasites, or tumor cells.

Results showed that after 48 weeks of treatment, both the doses of pegylated interferon lambda, also known as Lambda, led to either a reduction in the viral load or non-detection of any HDV-RNA.

Lambda enhances the retention time of treatments by protecting them against degrading inside a cell, which consequently improves their therapeutic potential.

The most common side effects from the treatment included mild to moderate flu-like symptoms and higher levels of transaminase enzymes — a potential sign of liver disease.

Lambda was better tolerated by HDV infected patients who were previously treated with alfa interferon, said study co-lead investigators Ohad Etzion and Saeed Hamid.

The drug's lower side effects also make it attractive for use as a monotherapy or in combination with other HDV treatments, they added.

There is currently no approved therapy for HDV infection, which affects up to about 15 million to 20 million people worldwide, the company said. It is considered to be one of the most severe forms of viral hepatitis in humans.

The Palo Alto, Calif.-based company is conducting another phase 2 study, called LIFT, to test a combination of interferon lambda and its lead candidate lonafarnib boosted with approved HIV-1 treatment ritonavir among HDV-infected patients.